Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CENTENE CORPCNC · Entity 3133 | President | July 04, 2024 | July 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CENTENE CORP
Report date July 04, 2024 · Filed July 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 286,066 |
Reported balance
After 2024-07-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-07-04 · Tax withholding · Disposed 14,291 · Balance 286,066 F1: Shares withheld for taxes upon vesting of previously-reported grant of restricted stock units. F2: Ownership includes 207,096 shares of previously-granted restricted stock units and performance stock units (reported at target level performance) subject to vesting requirements. |
| Phantom StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2023-03-10 | Direct | 3,605.628 |
Reported balance
Holding disclosure · report date 2024-07-04 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 3,605.628 F3: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F4: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Fasola's termination with the Company, or on such other date Mr. Fasola may elect. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares withheld for taxes upon vesting of previously-reported grant of restricted stock units.
F2: Ownership includes 207,096 shares of previously-granted restricted stock units and performance stock units (reported at target level performance) subject to vesting requirements.
F3: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock.
F4: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Fasola's termination with the Company, or on such other date Mr. Fasola may elect.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
MAGELLAN HEALTH INC
Report date January 04, 2022 · Filed January 04, 2022
Section 16 reporting ended · disclosed 2022-01-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-01-04 transaction · row 1
1 source rowRow 1 · 2022-01-04 · Disposition to issuer · Disposed 17,141 · Balance 0 F1: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-01-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-01-04 · Disposition to issuer · Disposed 8,580 · Balance 0 F2: Not applicable. F3: These unvested restricted stock units previously granted by the Issuer on December 2, 2019 , which provided for vesting on December 2, 2022, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-01-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-01-04 · Disposition to issuer · Disposed 22,196 · Balance 0 F2: Not applicable. F4: These unvested restricted stock units previously granted by the Issuer on March 4, 2020, which provided for vesting in equal increments on each of March 4, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-01-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-01-04 · Disposition to issuer · Disposed 43,080 · Balance 0 F2: Not applicable. F5: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-01-04 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2022-01-04 · Disposition to issuer · Disposed 18,411 · Balance 0 F2: Not applicable. F6: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on December 2, 2019 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. |
| Performance-Based Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2022-01-04 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-01-04 · Disposition to issuer · Disposed 27,743 · Balance 0 F2: Not applicable. F7: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 4, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration").
F2: Not applicable.
F3: These unvested restricted stock units previously granted by the Issuer on December 2, 2019 , which provided for vesting on December 2, 2022, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
F4: These unvested restricted stock units previously granted by the Issuer on March 4, 2020, which provided for vesting in equal increments on each of March 4, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
F5: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
F6: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on December 2, 2019 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
F7: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 4, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 04, 2024 Filed Jul 5, 2024 22:03 UTC | CENTENE CORP CNC · Entity 3133 | Tax withholdingCommon Stock | 14,291 | $66.76 | $954,067.16 |
DisclosureSEC source: 0001071739-24-000149 · wk-form4_1720217014.xml · nonDerivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,066 F1 · shares: Shares withheld for taxes upon vesting of previously-reported grant of restricted stock units. F2 · balance_after: Ownership includes 207,096 shares of previously-granted restricted stock units and performance stock units (reported at target level performance) subject to vesting requirements. Read SEC document |
| May 13, 2024 Filed May 15, 2024 22:10 UTC | CENTENE CORP CNC · Entity 3133 | SaleCommon Stock | 8,000 | $77.62 | $620,960.00 |
DisclosureSEC source: 0001071739-24-000106 · wk-form4_1715810999.xml · nonDerivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,357 F1 · price: The weighted average price for this transaction is reported within the form. Shares were sold at prices ranging from $77.42 to $77.98. Full information regarding the number of shares at each price is available upon request. F2 · balance_after: Ownership includes 243,417 shares of previously-granted restricted stock units and performance stock units (reported at target level performance) subject to vesting requirements. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 22:33 UTC | CENTENE CORP CNC · Entity 3133 | GrantCommon Stock | 79,224 | $0.00 | $0.00 |
DisclosureSEC source: 0001071739-24-000059 · wk-form4_1710887581.xml · nonDerivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 308,357 F2 · shares: This award includes 27,728 restricted stock units that vest in three annual installments on the anniversary of the grant date. This award also includes 51,496 performance stock units reported at target level performance. The actual number of performance stock units vesting on March 15, 2027, is predicated on meeting three-year performance conditions. F3 · balance_after: Ownership includes 164,193 shares of previously-granted restricted stock units and performance stock units (reported at target level of performance) subject to vesting requirements. Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 22:33 UTC | CENTENE CORP CNC · Entity 3133 | Tax withholdingCommon Stock | 6,232 | $76.05 | $473,943.60 |
DisclosureSEC source: 0001071739-24-000059 · wk-form4_1710887581.xml · nonDerivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,133 F1 · shares: Shares withheld for taxes upon vesting of previously-reported grant of restricted stock units. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 00:38 UTC | CENTENE CORP CNC · Entity 3133 | SaleCommon Stock | 3,810 | $75.58 | $287,959.80 |
DisclosureSEC source: 0001071739-24-000028 · wk-form4_1707439111.xml · nonDerivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 235,365 F2 · price: The weighted average price for this transaction is reported within the form. Shares were sold at prices ranging from $75.44 to $75.81. Full information regarding the number of shares at each price is available upon request. F3 · balance_after: Ownership includes 180,027 shares of restricted stock subject to vesting requirements. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 00:38 UTC | CENTENE CORP CNC · Entity 3133 | SaleCommon Stock | 8,190 | $74.83 | $612,857.70 |
DisclosureSEC source: 0001071739-24-000028 · wk-form4_1707439111.xml · nonDerivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 239,175 F1 · price: The weighted average price for this transaction is reported within the form. Shares were sold at prices ranging from $74.43 to $75.39. Full information regarding the number of shares at each price is available upon request. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 22:51 UTC | CENTENE CORP CNC · Entity 3133 | Tax withholdingCommon Stock | 7,001 | $76.60 | $536,276.60 |
DisclosureSEC source: 0001071739-24-000016 · wk-form4_1706050295.xml · nonDerivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 247,365 F1 · shares: Shares withheld for taxes upon vesting of previously reported stock grant. F2 · balance_after: Ownership includes 180,027 shares of restricted stock subject to vesting requirements. Read SEC document |
| January 04, 2024 Filed Jan 8, 2024 23:51 UTC | CENTENE CORP CNC · Entity 3133 | Tax withholdingCommon Stock | 14,373 | $77.21 | $1,109,739.33 |
DisclosureSEC source: 0001071739-24-000012 · wk-form4_1704757880.xml · nonDerivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,366 F1 · shares: Shares withheld for taxes upon vesting of previously reported stock grant. F2 · balance_after: Ownership includes 197,818 shares of restricted stock subject to vesting requirements. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 00:02 UTC | CENTENE CORP CNC · Entity 3133 | GrantCommon Stock | 95,123 | $63.34 | $6,025,090.82 |
DisclosureSEC source: 0001071739-23-000070 · wf-form4_167909774113554.xml · nonDerivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 268,739 F2 · balance_after: Ownership includes this award of 95,123 restricted stock units. 61,830 units are performance stock units. The number of performance stock units vesting at the end of the three year period is predicated on meeting three-year performance conditions. The remaining 33,293 units will vest in three annual installments on the anniversary of the grant date. In addition, ownership includes 139,015 shares of restricted stock units subject to vesting requirements. Read SEC document |
| March 15, 2023 Filed Mar 18, 2023 00:02 UTC | CENTENE CORP CNC · Entity 3133 | Tax withholdingCommon Stock | 1,865 | $63.34 | $118,129.10 |
DisclosureSEC source: 0001071739-23-000070 · wf-form4_167909774113554.xml · nonDerivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,616 F1 · shares: Shares withheld for taxes upon vesting of previously reported stock grant. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:53 UTC | CENTENE CORP CNC · Entity 3133 | GrantPhantom Stock · Derivative | 3,311.497 | $65.54 Strike: $0.00 | $217,035.51 |
DisclosureSEC source: 0001071739-23-000057 · wf-form4_167883077904676.xml · derivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,605.628 Underlying: Common Stock · 3,311.497 shares Expires 2023-03-10 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Fasola through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Fasola's termination with the Company, or on such other date Mr. Fasola may elect. Read SEC document |
| January 19, 2023 Filed Jan 24, 2023 00:47 UTC | CENTENE CORP CNC · Entity 3133 | Tax withholdingCommon Stock | 7,055 | $75.09 | $529,759.95 |
DisclosureSEC source: 0001071739-23-000021 · wf-form4_167452120496920.xml · nonDerivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,481 F1 · shares: Shares withheld for taxes upon vesting of previously reported stock grant. F2 · balance_after: Ownership includes 143,752 shares of restricted stock subject to vesting requirements. Read SEC document |
| December 23, 2022 Filed Dec 28, 2022 23:06 UTC | CENTENE CORP CNC · Entity 3133 | GrantPhantom Stock · Derivative | 24.319 | $82.24 Strike: $0.00 | $1,999.99 |
DisclosureSEC source: 0001071739-22-000399 · wf-form4_167226877198123.xml · derivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294.131 Underlying: Common Stock · 24.319 shares Expires 2022-12-23 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Fasola through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Fasola's termination with the Company, or on such other date Mr. Fasola may elect. Read SEC document |
| December 09, 2022 Filed Dec 13, 2022 23:51 UTC | CENTENE CORP CNC · Entity 3133 | GrantPhantom Stock · Derivative | 44.096 | $86.49 Strike: $0.00 | $3,813.86 |
DisclosureSEC source: 0001071739-22-000382 · wf-form4_167097548272074.xml · derivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · EVP, Health Care Enterprises 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 269.812 Underlying: Common Stock · 44.096 shares Expires 2022-12-09 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Fasola through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Fasola's termination with the Company, or on such other date Mr. Fasola may elect. Read SEC document |
| November 25, 2022 Filed Nov 30, 2022 00:00 UTC | CENTENE CORP CNC · Entity 3133 | GrantPhantom Stock · Derivative | 23.915 | $83.63 Strike: $0.00 | $2,000.01 |
DisclosureSEC source: 0001071739-22-000375 · wf-form4_166976641454902.xml · derivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · EVP, Health Care Enterprises 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225.716 Underlying: Common Stock · 23.915 shares Expires 2022-11-25 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Fasola through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Fasola's termination with the Company, or on such other date Mr. Fasola may elect. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 23:41 UTC | CENTENE CORP CNC · Entity 3133 | GrantPhantom Stock · Derivative | 23.843 | $83.88 Strike: $0.00 | $1,999.95 |
DisclosureSEC source: 0001071739-22-000366 · wf-form4_166855568264696.xml · derivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · EVP, Health Care Enterprises 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201.801 Underlying: Common Stock · 23.843 shares Expires 2022-11-10 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Fasola through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Fasola's termination with the Company, or on such other date Mr. Fasola may elect. Read SEC document |
| October 28, 2022 Filed Nov 1, 2022 23:20 UTC | CENTENE CORP CNC · Entity 3133 | GrantPhantom Stock · Derivative | 23.79 | $84.07 Strike: $0.00 | $2,000.03 |
DisclosureSEC source: 0001071739-22-000364 · wf-form4_166734478692149.xml · derivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · EVP, Health Care Enterprises 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177.958 Underlying: Common Stock · 23.79 shares Expires 2022-10-28 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Fasola through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Fasola's termination with the Company, or on such other date Mr. Fasola may elect. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 23:36 UTC | CENTENE CORP CNC · Entity 3133 | GrantPhantom Stock · Derivative | 26.575 | $75.26 Strike: $0.00 | $2,000.03 |
DisclosureSEC source: 0001071739-22-000354 · wf-form4_166613615103995.xml · derivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · EVP, Health Care Enterprises 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 154.168 Underlying: Common Stock · 26.575 shares Expires 2022-10-14 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Fasola through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Fasola's termination with the Company, or on such other date Mr. Fasola may elect. Read SEC document |
| September 30, 2022 Filed Oct 5, 2022 01:18 UTC | CENTENE CORP CNC · Entity 3133 | GrantPhantom Stock · Derivative | 26.162 | $77.68 Strike: $0.00 | $2,032.26 |
DisclosureSEC source: 0001071739-22-000350 · wf-form4_166493258018104.xml · derivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · EVP, Health Care Enterprises 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127.593 Underlying: Common Stock · 26.162 shares Expires 2022-09-30 F2 · derivative.exercise_price: Each share of phantom stock represents the right to receive the fair market value of one share of Centene common stock. F3 · shares: The phantom stock was acquired by Mr. Fasola through regularly scheduled payroll contributions to the Company's deferred compensation plan. F4 · derivative.expiration_date: The phantom stock has no formal expiration date. The phantom stock will be settled in cash or other non-Company securities upon Mr. Fasola's termination with the Company, or on such other date Mr. Fasola may elect. Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 17:08 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Disposition to issuerPerformance-Based Restricted Stock Units · Derivative | 27,743 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-22-000962 · doc4.xml · derivative · entry 6 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,743 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F7 · price: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 4, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F7 · derivative.exercise_date: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 4, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F2 · derivative.expiration_date: Not applicable. F7 · derivative.underlying_shares: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on March 4, 2020 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 17:08 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Disposition to issuerPerformance-Based Restricted Stock Units · Derivative | 18,411 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-22-000962 · doc4.xml · derivative · entry 5 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,411 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F6 · price: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on December 2, 2019 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F6 · derivative.exercise_date: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on December 2, 2019 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F2 · derivative.expiration_date: Not applicable. F6 · derivative.underlying_shares: These performance-vested restricted stock units of the Issuer that were previously reported in connection with an award granted on December 2, 2019 were disposed of in exchange for a number of time-vested restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 17:08 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Disposition to issuerRestricted Stock Units · Derivative | 43,080 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-22-000962 · doc4.xml · derivative · entry 4 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 43,080 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F5 · price: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F5 · derivative.exercise_date: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F2 · derivative.expiration_date: Not applicable. F5 · derivative.underlying_shares: These unvested restricted stock units previously granted by the Issuer on March 3, 2021, which provided for a one-third vesting of shares on each of March 3, 2022, 2023 and 2024, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 17:08 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Disposition to issuerRestricted Stock Units · Derivative | 22,196 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-22-000962 · doc4.xml · derivative · entry 3 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,196 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F4 · price: These unvested restricted stock units previously granted by the Issuer on March 4, 2020, which provided for vesting in equal increments on each of March 4, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F4 · derivative.exercise_date: These unvested restricted stock units previously granted by the Issuer on March 4, 2020, which provided for vesting in equal increments on each of March 4, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F2 · derivative.expiration_date: Not applicable. F4 · derivative.underlying_shares: These unvested restricted stock units previously granted by the Issuer on March 4, 2020, which provided for vesting in equal increments on each of March 4, 2022 and 2023, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 17:08 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Disposition to issuerRestricted Stock Units · Derivative | 8,580 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-22-000962 · doc4.xml · derivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,580 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F3 · price: These unvested restricted stock units previously granted by the Issuer on December 2, 2019 , which provided for vesting on December 2, 2022, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F3 · derivative.exercise_date: These unvested restricted stock units previously granted by the Issuer on December 2, 2019 , which provided for vesting on December 2, 2022, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. F2 · derivative.expiration_date: Not applicable. F3 · derivative.underlying_shares: These unvested restricted stock units previously granted by the Issuer on December 2, 2019 , which provided for vesting on December 2, 2022, were disposed of in exchange for a number of restricted stock units related to shares of Centene common stock, as determined in accordance with the Merger Agreement. Read SEC document |
| January 04, 2022 Filed Jan 4, 2022 17:08 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Disposition to issuerOrdinary Common Stock, $0.01 par value | 17,141 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-000962 · doc4.xml · nonDerivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration"). F1 · price: In connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of January 4, 2021 (the "Merger Agreement"), by and among the Issuer, Centene Corporation ("Centene") and Mayflower Merger Sub, Inc. ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly owned subsidiary of Centene, each share of the Issuer's common stock, par value $0.01 per share (the "Common Stock") outstanding immediately prior to the effective time of the Merger and not otherwise excluded pursuant to the terms of the Merger Agreement was disposed of in exchange for $95.00 per share in cash, without interest (the "Merger Consideration"). Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 17:13 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Exercise / conversionRestricted Stock Units · Derivative | 8,580 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-068132 · doc4.xml · derivative · entry 3 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,580 Underlying: Common Stock · 8,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not applicable. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit Award granted on December 2, 2019. Each Restricted Stock Unit represents a contingent right to receive one share of Magellan common stock. F2 · price: Not applicable. F5 · derivative.exercise_date: The remainder of 8,580 Restricted Stock Units shall vest on December 2, 2022, subject to earlier acceleration or forfeiture. F2 · derivative.expiration_date: Not applicable. F5 · balance_after: The remainder of 8,580 Restricted Stock Units shall vest on December 2, 2022, subject to earlier acceleration or forfeiture. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 17:13 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Tax withholdingOrdinary Common Stock, $0.01 par value | 3,376 | $94.62 | $319,437.12 |
DisclosureSEC source: 0001209191-21-068132 · doc4.xml · nonDerivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,141 F3 · kind: Represents the portion of shares withheld by the Company in order to pay taxes. F4 · price: Closing price on NASDAQ on December 2, 2021. Read SEC document |
| December 02, 2021 Filed Dec 6, 2021 17:13 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Exercise / conversionOrdinary Common Stock, $0.01 par value | 8,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-068132 · doc4.xml · nonDerivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,517 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit Award granted on December 2, 2019. Each Restricted Stock Unit represents a contingent right to receive one share of Magellan common stock. F2 · price: Not applicable. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 18:43 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Exercise / conversionRestricted Stock Units · Derivative | 11,099 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018368 · doc4.xml · derivative · entry 4 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,196 Underlying: Common Stock · 11,099 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not applicable. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit award granted on March 4, 2020. Each Restricted Stock Unit represents a contingent right to receive one share of Magellan common stock. F2 · price: Not applicable. F6 · derivative.exercise_date: The remainder of 22,196 Restricted Stock Units shall vest in equal increments on March 4, 2022 and 2023, subject to earlier acceleration or forfeiture. F2 · derivative.expiration_date: Not applicable. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 18:43 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Tax withholdingOrdinary Common Stock, $0.01 par value | 4,366 | $93.47 | $408,090.02 |
DisclosureSEC source: 0001209191-21-018368 · doc4.xml · nonDerivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,937 F3 · kind: Represents the portion of shares withheld by the Company in order to pay taxes. F4 · price: Closing price on NASDAQ on March 4, 2021. Read SEC document |
| March 04, 2021 Filed Mar 5, 2021 18:43 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Exercise / conversionOrdinary Common Stock, $0.01 par value | 11,099 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018368 · doc4.xml · nonDerivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit award granted on March 4, 2020. Each Restricted Stock Unit represents a contingent right to receive one share of Magellan common stock. F2 · price: Not applicable. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 18:43 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantRestricted Stock Units · Derivative | 43,080 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-018368 · doc4.xml · derivative · entry 3 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,080 Underlying: Common Stock · 43,080 shares Expires not disclosed F2 · derivative.exercise_price: Not applicable. F2 · price: Not applicable. F5 · derivative.exercise_date: Restricted Stock Units vest and become exercisable in one third increments on March 3rd of each of 2022, 2023 and 2024, subject to earlier acceleration or forfeiture. F2 · derivative.expiration_date: Not applicable. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 16:09 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Exercise / conversionRestricted Stock Units · Derivative | 8,580 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061789 · doc4.xml · derivative · entry 3 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,160 Underlying: Common Stock · 8,580 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Not applicable. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit Award granted on December 2, 2019. Each Restricted Stock Unit represents a contingent right to receive one share of Magellan common stock. F2 · price: Not applicable. F5 · derivative.exercise_date: The remainder of 17,160 Restricted Stock Units shall vest in equal increments on December 2, 2021 and 2022. F2 · derivative.expiration_date: Not applicable. F5 · balance_after: The remainder of 17,160 Restricted Stock Units shall vest in equal increments on December 2, 2021 and 2022. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 16:09 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Tax withholdingOrdinary Common Stock, $0.01 par value | 3,376 | $78.55 | $265,184.80 |
DisclosureSEC source: 0001209191-20-061789 · doc4.xml · nonDerivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,204 F3 · kind: Represents the portion of shares withheld by the Company in order to pay taxes. F4 · price: Closing price on NASDAQ on December 2, 2020. Read SEC document |
| December 02, 2020 Filed Dec 4, 2020 16:09 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | Exercise / conversionOrdinary Common Stock, $0.01 par value | 8,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-061789 · doc4.xml · nonDerivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,580 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effectuated by a one-third vesting of the Restricted Stock Unit Award granted on December 2, 2019. Each Restricted Stock Unit represents a contingent right to receive one share of Magellan common stock. F2 · price: Not applicable. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 16:11 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantRestricted Stock Units · Derivative | 33,295 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016900 · doc4.xml · derivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,295 Underlying: Common Stock · 33,295 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F1 · price: Not applicable. F4 · derivative.exercise_date: Restricted Stock Units vest in one third increments on March 4th of each of 2021, 2022 and 2023. F1 · derivative.expiration_date: Not applicable. Read SEC document |
| March 04, 2020 Filed Mar 6, 2020 16:11 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantPerformance-Based Restricted Stock Units · Derivative | 27,743 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-016900 · doc4.xml · derivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,743 Underlying: Common Stock · 27,743 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F1 · price: Not applicable. F2 · derivative.expiration_date: On the third anniversary of the grant date, Performance-Based Restricted Stock Units ("PSUs") vest based on achievement of total shareholder return ("TSR") performance relative to the S&P Health Services Industry Index over a three-year period beginning in 2020 and ending in 2022. Payout for vested PSUs ranges from 0% to 200% of the indicated number of shares, based on the Company's TSR percentile ranking compared to the TSR of the companies included in the selected market index. TSR is measured generally as the increase or decrease in the market value of the Company common stock with a deemed reinvestment of any dividends. If a participant terminates employment prior to the third anniversary of the grant date, the PSUs generally will be forfeited. PSUs have no voting rights and are generally non-transferable. The indicated number of PSUs assumes 100% vesting, and the actual number of shares issued in settlement of the PSUs may be greater or less than the indicated number. F3 · derivative.expiration_date: (Continuation of Footnote 3) - Since the payout for PSUs can range from 0% to 200%, the maximum number of shares that could vest and be issued could be double the indicated number. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 11:30 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantPerformance Stock Units · Derivative | 18,411 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-058964 · doc4.xml · derivative · entry 2 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,411 Underlying: Common Stock · 18,411 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F1 · price: Not applicable. F3 · derivative.expiration_date: On the third anniversary of the grant date, Performance-Based Restricted Stock Units ("PSUs") vest and are settled as of January 10, 2023 based on achievement of total shareholder return ("TSR") performance over a three-year period beginning January 1, 2020 and ending December 31, 2022. Payout for vested PSUs ranges from 0% to 200% of the indicated number of shares, based on the Company's TSR percentile ranking compared to the TSR of the companies included in the selected market index. TSR is measured generally as the increase or decrease in the market value of the Company common stock with a deemed reinvestment of any dividends. If a participant terminates employment prior to the third anniversary of the grant date, the PSUs generally will be forfeited. PSUs have no voting rights and are generally non-transferable. The indicated number of PSUs assumes 100% vesting, and the actual number of shares issued in settlement of the PSUs may be greater or less than the indicated number. F4 · derivative.expiration_date: (Continuation of Footnote 3) - Since the payout for PSUs can range from 0% to 200%, the maximum number of shares that could vest and be issued could be double the indicated number. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 11:30 UTC | MAGELLAN HEALTH INC MGLN · Entity 131790 | GrantRestricted Stock Units · Derivative | 25,740 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-058964 · doc4.xml · derivative · entry 1 FASOLA KENNETH J · CIK 0001030150 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,740 Underlying: Common Stock · 25,740 shares Expires not disclosed F1 · derivative.exercise_price: Not applicable. F1 · price: Not applicable. F2 · derivative.exercise_date: Restricted Stock Units shall vest and become exercisable in one third increments on December 2 of each of 2020, 2021 and 2022. F1 · derivative.expiration_date: Not applicable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.